Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Disease Progression

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

All Drugs and Chemicals

Mitogens

Patients in the group were treated with both targeted therapy and microwave ablation. Patients were treated with Almonertinib with the dose of 110mg once daily firstly. When the best response achieved, microwave ablation was conducted in the primary tumors, and then followed by Almonertinib treatments.

Patients in the group were treated with Almonertinib with the dose of 110mg once daily until disease progression, death or intolerable adverse events.

Patients were treated with almonertinib firstly.When almonertinib achieved the maximal response, microwave ablation was conducted on the primary lung tumors.

Almonertinib plus microwave ablation

Xin Ye

Zhigang Wei

Almonertinib, as a third-generation EGFR-TKI, has been used for the treatment of advanced non small cell lung cancer. How to improve the progression free survival in advance was a challenge. Our previous study showed that first-line EGFR-TKIs plus microwave ablation had PFS survival advantage versus EGFR-TKIs alone. So we conducted this prospective study to verify the efficacy and safety of the combination in a randomized, controlled, phase II clinical trial.

Almonertinib, as a third-generation EGFR-TKI, has been used for the treatment of advanced non small cell lung cancer. How to improve the progression free survival in advance was a challenge. Our previous study showed that first-line EGFR-TKIs plus microwave ablation had PFS survival advantage versus EGFR-TKIs alone. So we conducted this prospective study to verify the efficacy and safety of the combination in a randomized, controlled, phase II clinical trial. Patients were assigned into two groups.In the experiment group, patients were treated with both Almonertinib and microwave ablation. In the control group, patients were treated with Almonertinib alone. The primary end point was progression free survival. Second endpoints included overall survival and safety.

Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer

Almonertinib Plus Microwave Ablation Versus Almonertinib in Previously Untreated，Advanced Non-small Cell Lung Cancer, a Randomized，Controlled，Phase II Clinical Trial

Shandong Provincial Hospital

Qianfoshan Hospital

Head of the department of oncology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer	NCT04755738	Advanced Non Sm...	Almonertinib pl...	18 Years - 80 Years	Qianfoshan Hospital
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer	NCT04755738	Advanced Non Sm...	Almonertinib pl...	18 Years - 80 Years	Qianfoshan Hospital
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer	NCT04755738	Advanced Non Sm...	Almonertinib pl...	18 Years - 80 Years	Qianfoshan Hospital

Spots Global Cancer Trial Database for almonertinib plus microwave ablation